ORAL VANCOMYCIN FOR ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS

Francis Tedesco, Marc Gurwith, Richard Markham, Dennis Christie, John Bartlett

Research output: Contribution to journalArticle

Abstract

Nine patients with antibiotic-associated pseudomembranous colitis were treated with oral vancomycin. All had severe diarrhœa, tissue-culture evidence of a clostridial toxin in stool, and typical lesions on sigmoidoscopic examination, despite discontinuation of all antimicrobials for periods of 10 days to 8 weeks. Oral vancomycin was given in doses of 2 g daily. All patients showed a good clinical response with gradual resolution of diarrhœa over 7 days and a rapid decrease in concentrations of the toxin in stools. Follow-up sigmoidoscopies in seven patients showed major improvement or complete clearing of lesions after 7-10 days of vancomycin treatment. The mean concentration of vancomycin in twenty-five stools obtained during treatment was 3100 μg/g, levels in serum being very low. These results suggest a role for oral vancomycin treatment of antibiotic-associated pseudomembranous colitis which persists for extended periods despite discontinuation of the incriminated antimicrobial.

Original languageEnglish (US)
Pages (from-to)226-228
Number of pages3
JournalThe Lancet
Volume312
Issue number8083
DOIs
StatePublished - Jul 29 1978
Externally publishedYes

Fingerprint

Pseudomembranous Enterocolitis
Vancomycin
Sigmoidoscopy
Therapeutics
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

ORAL VANCOMYCIN FOR ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS. / Tedesco, Francis; Gurwith, Marc; Markham, Richard; Christie, Dennis; Bartlett, John.

In: The Lancet, Vol. 312, No. 8083, 29.07.1978, p. 226-228.

Research output: Contribution to journalArticle

Tedesco, F, Gurwith, M, Markham, R, Christie, D & Bartlett, J 1978, 'ORAL VANCOMYCIN FOR ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS', The Lancet, vol. 312, no. 8083, pp. 226-228. https://doi.org/10.1016/S0140-6736(78)91741-5
Tedesco, Francis ; Gurwith, Marc ; Markham, Richard ; Christie, Dennis ; Bartlett, John. / ORAL VANCOMYCIN FOR ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS. In: The Lancet. 1978 ; Vol. 312, No. 8083. pp. 226-228.
@article{57d0fc767a03486d9765f3d2246f9cb5,
title = "ORAL VANCOMYCIN FOR ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS",
abstract = "Nine patients with antibiotic-associated pseudomembranous colitis were treated with oral vancomycin. All had severe diarrhœa, tissue-culture evidence of a clostridial toxin in stool, and typical lesions on sigmoidoscopic examination, despite discontinuation of all antimicrobials for periods of 10 days to 8 weeks. Oral vancomycin was given in doses of 2 g daily. All patients showed a good clinical response with gradual resolution of diarrhœa over 7 days and a rapid decrease in concentrations of the toxin in stools. Follow-up sigmoidoscopies in seven patients showed major improvement or complete clearing of lesions after 7-10 days of vancomycin treatment. The mean concentration of vancomycin in twenty-five stools obtained during treatment was 3100 μg/g, levels in serum being very low. These results suggest a role for oral vancomycin treatment of antibiotic-associated pseudomembranous colitis which persists for extended periods despite discontinuation of the incriminated antimicrobial.",
author = "Francis Tedesco and Marc Gurwith and Richard Markham and Dennis Christie and John Bartlett",
year = "1978",
month = "7",
day = "29",
doi = "10.1016/S0140-6736(78)91741-5",
language = "English (US)",
volume = "312",
pages = "226--228",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8083",

}

TY - JOUR

T1 - ORAL VANCOMYCIN FOR ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS

AU - Tedesco, Francis

AU - Gurwith, Marc

AU - Markham, Richard

AU - Christie, Dennis

AU - Bartlett, John

PY - 1978/7/29

Y1 - 1978/7/29

N2 - Nine patients with antibiotic-associated pseudomembranous colitis were treated with oral vancomycin. All had severe diarrhœa, tissue-culture evidence of a clostridial toxin in stool, and typical lesions on sigmoidoscopic examination, despite discontinuation of all antimicrobials for periods of 10 days to 8 weeks. Oral vancomycin was given in doses of 2 g daily. All patients showed a good clinical response with gradual resolution of diarrhœa over 7 days and a rapid decrease in concentrations of the toxin in stools. Follow-up sigmoidoscopies in seven patients showed major improvement or complete clearing of lesions after 7-10 days of vancomycin treatment. The mean concentration of vancomycin in twenty-five stools obtained during treatment was 3100 μg/g, levels in serum being very low. These results suggest a role for oral vancomycin treatment of antibiotic-associated pseudomembranous colitis which persists for extended periods despite discontinuation of the incriminated antimicrobial.

AB - Nine patients with antibiotic-associated pseudomembranous colitis were treated with oral vancomycin. All had severe diarrhœa, tissue-culture evidence of a clostridial toxin in stool, and typical lesions on sigmoidoscopic examination, despite discontinuation of all antimicrobials for periods of 10 days to 8 weeks. Oral vancomycin was given in doses of 2 g daily. All patients showed a good clinical response with gradual resolution of diarrhœa over 7 days and a rapid decrease in concentrations of the toxin in stools. Follow-up sigmoidoscopies in seven patients showed major improvement or complete clearing of lesions after 7-10 days of vancomycin treatment. The mean concentration of vancomycin in twenty-five stools obtained during treatment was 3100 μg/g, levels in serum being very low. These results suggest a role for oral vancomycin treatment of antibiotic-associated pseudomembranous colitis which persists for extended periods despite discontinuation of the incriminated antimicrobial.

UR - http://www.scopus.com/inward/record.url?scp=0018104816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018104816&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(78)91741-5

DO - 10.1016/S0140-6736(78)91741-5

M3 - Article

C2 - 79026

AN - SCOPUS:0018104816

VL - 312

SP - 226

EP - 228

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8083

ER -